Originally distributed for the treatment of type 2 diabetes, GLP-1 medications have since been used on a widespread level for addressing obesity and helping patients achieve their weight loss goals
Researchers are investigating: Supply Challenges and Compounding As the use of semaglutide expands into new applications, supply challenges may arise, affecting access for menopausal and perimenopausal women seeking weight management solutions
In addition, functional study demonstrated that local injection of GLP-1 into the BNST induces food suppression during the dark phase (Williams et al., 2018)
Typical applications include: Obesity and Body-Weight Regulation Models : Studying how chronic AOD 9604 exposure affects body weight, fat, and energy expenditure in obese rodents, often using indirect calorimetry and body composition analyses
The MHRA states that products sold outside authorised clinical trials that claim to contain retatrutide are likely to be illegal and potentially dangerous